Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Mroz, A. Tycinska, P. Lisowski, J. Bierla, L. Minarowski, R. Milewski, A. Lisowska, P. Boros, E. Chyczewska, W. MacNee (Bialystok, , Jastrzebiec, Warsaw, Poland; Edinburgh, United Kingdom). Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients. Eur Respir J 2012; 40: Suppl. 56, 2883

Member's Comments

No comment yet.

Related content which might interest you: Pleiotropic effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Effects of add-on treatment with budesonide/formoterol combination in eosinophilic COPD patients Source: International Congress 2017 – Management of COPD Year: 2017 Evening administration of tiotropium during combination therapy reduces night-symptoms in COPD patients Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids? Source: Annual Congress 2007 - Treatment of COPD Year: 2007 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Initial anticholinergic therapy COPD Source: Eur Respir J 2006; 28: Suppl. 50, 29s Year: 2006 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015